Novartis stock (CH0012005267): Earnings miss and analyst downgrades weigh on pharma giant

Novartis reported first-quarter 2026 results that fell short of prior-year performance, with earnings per share declining and revenue remaining flat year-over-year. The results have triggered analyst downgrades and elevated implied volatility in the company's options market, signaling investor caution around the pharmaceutical giant's near-term trajectory.

According to Simply Wall St as of May 13, 2026, Novartis posted first-quarter 2026 earnings per share of $1.65, down from $1.83 in the same quarter of 2025. Revenue came in at $13.5 billion, flat compared to the prior-year quarter, while net income declined 13% to $3.16 billion.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Novartis AG: core business model

Novartis is one of the world's largest pharmaceutical companies, operating across innovative medicines, oncology, immunology, ophthalmology, and generic pharmaceuticals. The company serves patients globally through a diversified portfolio designed to address unmet medical needs across multiple therapeutic areas. As a major player in the US pharmaceutical market, Novartis generates substantial revenue from American healthcare systems and maintains significant manufacturing and research operations in the United States.

Analyst downgrades and earnings revisions

Over the last 30 days, two analysts have revised their earnings estimates downward for the current quarter, according to Zacks as of May 13, 2026. The downgrades reduced first-quarter 2026 EPS estimates from $2.28 to $2.21 per share, reflecting weaker-than-expected operational performance. Analysts maintain a 'Hold' rating on the stock as the company navigates margin pressures and revenue headwinds in key markets.

Options market volatility and investor sentiment

Implied volatility in Novartis stock options has surged in recent trading, a sign that investors are pricing in elevated uncertainty around the company's near-term direction. The combination of earnings misses, analyst downgrades, and margin contraction has created a cautious environment for equity holders. The stock traded at 115.90 Swiss Francs on May 12, 2026, according to market data, representing a 1.93% gain on the day but reflecting broader consolidation after the earnings disappointment.

US expansion plans amid operational challenges

Despite near-term headwinds, Novartis committed $23 billion over five years in April 2025 to expand its US research and manufacturing footprint, according to Business Facilities as of May 13, 2026. The plan includes seven new facilities and three expanded locations across the United States, underscoring the company's long-term commitment to American operations and innovation despite current earnings pressures.

Conclusion

Novartis faces a period of near-term uncertainty following first-quarter 2026 results that disappointed on both earnings and revenue metrics. Analyst downgrades and elevated options volatility reflect investor caution, though the company's substantial $23 billion US expansion commitment signals confidence in long-term growth. US investors holding or considering Novartis should monitor upcoming quarterly guidance and margin trends closely, as the pharmaceutical sector remains competitive and execution risks persist.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.